Lakeshore Biopharma (NASDAQ:LSB) Shares Down 2.8% – Here’s What Happened

Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) traded down 2.8% on Friday . The company traded as low as $2.17 and last traded at $2.13. 230 shares were traded during mid-day trading, a decline of 98% from the average session volume of 10,323 shares. The stock had previously closed at $2.19.

Lakeshore Biopharma Price Performance

The company has a debt-to-equity ratio of 0.13, a current ratio of 1.17 and a quick ratio of 0.90. The stock’s 50 day moving average is $2.60 and its two-hundred day moving average is $3.47.

Hedge Funds Weigh In On Lakeshore Biopharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LSB. Barclays PLC acquired a new position in Lakeshore Biopharma in the 3rd quarter worth $169,000. Orbimed Advisors LLC acquired a new position in Lakeshore Biopharma in the 4th quarter worth $486,000. Hhlr Advisors LTD. acquired a new position in Lakeshore Biopharma in the 3rd quarter worth $513,000. Finally, FMR LLC acquired a new position in Lakeshore Biopharma in the 3rd quarter worth $803,000. 52.64% of the stock is owned by institutional investors and hedge funds.

About Lakeshore Biopharma

LakeShore Biopharma Co, Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People’s Republic of China and Other Countries or Regions.